Clinical research of bone marrow-derived mesenchymal stem cell transplantation for the patients with epidermolysis bullosa.

Clinical research of bone marrow-derived mesenchymal stem cell transplantation for the patients with epidermolysis bullosa. - Clinical research of bone marrow-derived mesenchymal stem cell transplantation for the patients with epidermolysis bullosa.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006723

Enrollment

Registered

2011-11-14

Start date

2013-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis bullosa (junctional, dystrophic)

Interventions

Subcutaneous transplantation of bone marrow mesenchymal stem cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with epidermolysis bullosa (junctional or dystrophic type). 2) Patients aged 20-60 years old. 3) Patients with intractable skin ulcer which present for more than 6 weeks. 4) Patients who have opposite-sex parent or sibling with donor agreement. 5) Patients who agreed with written concent

Exclusion criteria

Exclusion criteria: 1) Patients with severe psychotic disorders 2) Patients with alcoholic addiction 3) Patients with disturbance of consciousness 4) Patients with history of malignancy within the last 5 years 5) Patients with pregnancy 6) Patients with diabetes Other patients who are evaluated not to be suitable for this research

Design outcomes

Primary

Measure	Time frame
Safety evaluation (Adverse events)	—

Secondary

Measure	Time frame
Efficacy evaluation (macroscopic and histological examination of the skin lesions)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026